From human genome
to genetic medicines

UNDRUGGABLE

Most diseases are undruggable with biologic or small molecule approaches, leaving millions of patients with limited options. Precision genetic medicines represent a new class of therapies that target the DNA mutations that drive disease. Nearly all diseases are caused by genetic changes, underscoring the critical importance of new medicines that can “drug the genome” for the future of health.

At NeuBase, we are advancing an entirely new class of medicines to address many currently undruggable diseases. NeuBase’s ultra-precision genetic medicines have demonstrated, in proof-of-concept preclinical studies, treatment tolerability, selective engagement of different disease-driving mutations, and broad tissue distribution after systemic administration. With our platform, we have the potential to address a wide range of diseases, from rare to common.

The Human Genome: From Foundation to Future Medicines

The world’s collective knowledge of the human genome, and our ability to apply that knowledge to the development of medicines that can cure disease and mitigate suffering, is nothing less than extraordinary. In less than 20 years, we’ve been part of the mapping of the human genome, identifying the genetic mutations causing thousands of diseases, and developing new medicines that can target these mutations. All of our work has led us to today, where our dedicated and experienced team is working to create a world where no patient is without a meaningful therapy.

LEADERSHIP

Dietrich A. Stephan, Ph.D.

CEO, Founder, & Director

Dietrich A. Stephan, Ph.D.

CEO, Founder, & Director

Dr. Stephan is an industry veteran having had a career spanning genomics research, translation, and commercial development of healthcare solutions. During his research career, Stephan has served as professor and chairman of the Department of Human Genetics at the University of Pittsburgh, the 3rd top NIH-funded university in the USA in fiscal year 2022, and has held academic affiliations with Harvard Medical School, Johns Hopkins University and Children’s National Medical Center. During his research career, Dr. Stephan has identified the genetic basis of dozens of rare and common diseases, developed new genomics technologies, and participated in large multi-institutional collaborations, with approximately 150 peer-reviewed publications. In his translational roles, Dr. Stephan served as Deputy Director for Discovery Research at the Translational Genomics Research Institute (TGen), where he oversaw all programmatic divisions and established and directed the Neurogenomics Division to address neurological and mental health disorders. In addition, Dr. Stephan has contributed to various translational institutes including founding the Cancer Genome Institute at Fox Chase Cancer Center, crafting the vision and leading the early coalition-building with partners resulting in the New York Genome Center, and founding a translational institute in the Washington DC region. These efforts have led to new molecular diagnostics and targeted therapeutics, created thousands of jobs, and nucleated bio clusters. Dr. Stephan has founded, co-founded, advised, and led as CEO or Chairman several biotechnology companies including Amnestix (acquired by Syngis AG), Navigenics (acquired by Life Technologies), LifeCode (acquired by MedGenome), Genia Technologies (acquired by Roche), iGenomX (acquired by Twist), JumpCode, Pendulum Therapeutics, Guardant Health, Peptilogics, Sharp Therapeutics, Navio Theragnostics, FarmaceuticalRx, and others. Many of these companies are delivering diagnostics and therapeutics that are benefiting patients across the globe. Dr. Stephan received his B.Sc. from Carnegie Mellon University, his Ph.D. from the University of Pittsburgh, and did his fellowship at the National Human Genome Research Institute of the National Institutes of Health.

Todd P. Branning

Chief Financial Officer

Todd P. Branning

Chief Financial Officer

Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc., a publicly traded late clinical-stage biopharmaceutical company. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger. From 2013-2018, Mr. Branning worked as a divisional CFO, firstly for Actavis plc, during which time he worked on Actavis’ acquisitions of Forest Laboratories for ~$25B and Allergan plc for approximately $66B, then for Teva Pharmaceuticals following its acquisition of Allergan’s generics business for approximately $40B, which Mr. Branning also worked on. While at Teva, he was Senior Vice President, CFO of the global generic medicines division, where he led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva’s largest multi-billion-dollar commercial unit. Mr. Branning has also held financial leadership roles at PricewaterhouseCoopers LLP, PPG Industries, Inc., and Merck & Co., Inc. Mr. Branning received his BBA from the University of Miami and MBA from Carnegie Mellon University. Mr. Branning is also a Certified Public Accountant and has completed a CFO certification program at The Wharton School at the University of Pennsylvania.

BOARD OF DIRECTORS

Dov A. Goldstein, M.D., M.B.A.

Chairperson

Dov A. Goldstein, M.D., M.B.A.

Chairperson

Dr. Goldstein has served as a member of our board of directors since July 2019. Dr. Goldstein is Chief Financial Officer of BioAge Labs and a director of Coya Therapeutics (Nasdaq: COYA) and Gain Therapeutics (Nasdaq: GANX).  He was previously Chief Financial Officer of Indapta Therapeutics. Dr. Goldstein previously was the Chief Financial Officer at Schrödinger, LLC from the fourth quarter of 2017 to the second quarter of 2018. Dr. Goldstein served as a Managing Partner at Aisling Capital, a private investment firm, from 2014 to October 2017, Partner from 2008 to 2014, and a principal at Aisling Capital from 2006 to 2008. Dr. Goldstein served as the Chief Financial Officer of LoxoOncology, Inc. between July 2014 and January 2015 and was its acting Chief Financial Officer from January 2015 to May 2015. Goldstein was a founder and investor in Durata Therapeutics, acquired by Actavis for $675M, and an investor and board member of Topaz Pharmaceuticals, acquired by Sanofi Pasteur. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005 for $1.9B. Prior to joining Vicuron, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures. Dr. Goldstein also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital. Dr. Goldstein serves as a director at ADMA Biologics, Inc. (Nasdaq: ADMA). He also previously served as a director of Loxo Oncology, Inc. (Nasdaq: LOXO), Esperion Therapeutics, Inc. (Nasdaq: ESPR), and Cempra, Inc. (which was acquired by Melinta Therapeutics, Inc.). Dr. Goldstein has been an executive or director of companies that have brought to market: Dalvance®, Eraxis®, Nulexetol® and Sklice®. Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School, and an M.D. from Yale School of Medicine.

Gerald J. McDougall

Director

Gerald J. McDougall

Director

Mr. McDougall’s passion is to link scientific breakthroughs to clinical application for the benefit of patients and society. For more than 25 years, he has been the driving force behind large-scale strategic alliances, joint ventures, and industry partnerships across the healthcare industry to advance innovations in precision medicine and cancer. He has spent almost his entire career as a senior partner at PricewaterhouseCoopers (PwC) where he built and led the firm’s Global Health Science consulting practice before retiring. He has worked across the entire ecosystem of the healthcare industry and advised an array of Fortune 500 companies, including leading global pharmaceutical companies. Mr. McDougall has been instrumental around the globe in building public-private partnerships to address human health imperatives. These include the creation and maturation of the Translational Genomics Research Institute (TGen), Arizona’s renowned bio-cluster; the design and launch of the Multiple Myeloma Research Consortium (MMRC); the strategic plan for the California Institute of Regenerative Medicine (CIRM) and the Country of Luxemburg’s biotechnology commercialization ecosystem.

Eric Richman, M.B.A.

Director

Eric Richman, M.B.A.

Director

Mr. Richman brings to Neubase more than 30 years of industry experience including venture investing, project and organizational management, business development, commercialization and strategic planning.   Mr. Richman began his career at HealthCare Ventures – a life science focussed investment firm that formed several transformation companies. He was part of the founding team at MedImmune (acquired by AZ) and then held various operating and board roles in companies including LEV Pharma (acquired by Viropharma), PharmAthene (acquired by Altimmune), MaxCyte, Adma Biologics, American Bank (acquired by Congressional Bancshares) and others.  He was involved in taking 5 companies public and now serves on the Board of Gain Therapeutics, LabConnect, Inc., Horizon Infusions, Microhealth, Novelstem and others.  His commercial experience includes the launches of rare disease drugs: CytoGama®, RespiGama®, Synagisa®, Cinryzea®, Asceniva®, Zosyna®, Ethyola®, Hexalina® and others.  He served Venture Partner at Brace Pharma Capital and is currently an advisor to Broad Oak Capital and Venture Partner at Allele Capital.   Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a MBA from the American Graduate School of International Management (ASU).

Dietrich A. Stephan, Ph.D.

CEO, Founder, & Director

Dietrich A. Stephan, Ph.D.

CEO, Founder, & Director

Dr. Stephan is an industry veteran having had a career spanning genomics research, translation, and commercial development of healthcare solutions. During his research career, Stephan has served as professor and chairman of the Department of Human Genetics at the University of Pittsburgh, the 3rd top NIH-funded university in the USA in fiscal year 2022, and has held academic affiliations with Harvard Medical School, Johns Hopkins University and Children’s National Medical Center. During his research career, Dr. Stephan has identified the genetic basis of dozens of rare and common diseases, developed new genomics technologies, and participated in large multi-institutional collaborations, with approximately 150 peer-reviewed publications. In his translational roles, Dr. Stephan served as Deputy Director for Discovery Research at the Translational Genomics Research Institute (TGen), where he oversaw all programmatic divisions and established and directed the Neurogenomics Division to address neurological and mental health disorders. In addition, Dr. Stephan has contributed to various translational institutes including founding the Cancer Genome Institute at Fox Chase Cancer Center, crafting the vision and leading the early coalition-building with partners resulting in the New York Genome Center, and founding a translational institute in the Washington DC region. These efforts have led to new molecular diagnostics and targeted therapeutics, created thousands of jobs, and nucleated bio clusters. Dr. Stephan has founded, co-founded, advised, and led as CEO or Chairman several biotechnology companies including Amnestix (acquired by Syngis AG), Navigenics (acquired by Life Technologies), LifeCode (acquired by MedGenome), Genia Technologies (acquired by Roche), iGenomX (acquired by Twist), JumpCode, Pendulum Therapeutics, Guardant Health, Peptilogics, Sharp Therapeutics, Navio Theragnostics, FarmaceuticalRx, and others. Many of these companies are delivering diagnostics and therapeutics that are benefiting patients across the globe. Dr. Stephan received his B.Sc. from Carnegie Mellon University, his Ph.D. from the University of Pittsburgh, and did his fellowship at the National Human Genome Research Institute of the National Institutes of Health.